Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- ChecktodayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check15 days agoChange DetectedThe webpage has been updated to reflect new results and timelines for a clinical study involving Sacituzumab Govitecan and Pembrolizumab in HR+ / HER2- metastatic breast cancer, with a new data cutoff date and revised reporting dates.SummaryDifference12%
- Check22 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.